Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs SGMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMT Captures Overall Composite Edge (43.1 HOLD vs 49.0 HOLD), While VNDA Leads 3–2 on Growth & Valuation Pillars

SGMT Overall Winner 6-Pillar Tally: VNDA 3 – 2 SGMT (1 Tie) Matrix Metrics: VNDA 5 – 5 SGMT

As of Nov 16, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (43.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus SGMT at $10.29 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. SGMT 43.1/100 HOLD), SGMT captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -77.6% operating margin) and revenue trajectory (+0.0% vs. +24.1% YoY).
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SGMT trades in a Neutral technical trend (BREAKOUT options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs SGMT
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
SGMT NASDAQ Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$10.29
+0.68% 1D
Market Cap $775.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.05β · 84% Vol
Unified Composite Score
43.1 / 100 HOLD
Tech 15.0 Fund 46.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $10.17 · SMA50: $9.86

6-Pillar Scorecard Institutional Category Breakdown (VNDA 3 – 2 SGMT)

Columns: Metric · VNDA · SGMT
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x N/M
PEG Ratio 2.23x N/M
EV / Revenue 0.9x N/M
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% +0.0%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M N/A
Market Cap $238.9M $775.0M
3. Profitability & Quality SGMT
Gross Margin 93.6% N/A
Operating Margin -77.6% 0.0%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -24.4%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$44M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $109M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMT
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 163.3% (75th %ile) 83.2% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (5) vs SGMT (5)
Institutional Metric VNDA SGMT Criterion Row Edge
Market Capitalization
Scale
$238.9M $775.0M Larger Scale SGMT
Trailing P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% +0.0% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% 0.0% Higher Margin SGMT
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin SGMT
Return on Equity (ROE)
Capital Efficiency
-82.5% -24.4% Higher ROE SGMT
52-Week Range Position
Momentum
4% ($4–$10) 83% ($4–$11) Stronger Trend SGMT
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 2.05β · 84% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 43.1 / 100 (HOLD) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$44M ($109M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGMT +34.13 pp
VNDA: -5.83% · SGMT: +28.3%
3M Horizon SGMT +27.5 pp
VNDA: -30.24% · SGMT: -2.74%
6M Horizon SGMT +92.08 pp
VNDA: -37.58% · SGMT: +54.5%
1Y Horizon SGMT +45.51 pp
VNDA: -12.56% · SGMT: +32.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue SGMT Revenue VNDA Op. Margin SGMT Op. Margin Margin Leader
FY2018 $190M N/A 11.3% N/A VNDA
FY2019 $230M N/A 10.0% N/A VNDA
FY2020 $250M N/A 11.0% N/A VNDA
FY2021 $270M N/A 15.7% N/A VNDA
FY2022 $250M N/A 2.5% N/A VNDA
FY2023 $190M $0M -7.2% -1537.0% VNDA
FY2024 $200M N/A -20.5% N/A VNDA
FY2025 $220M N/A -70.0% N/A VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMT BREAKOUT
140d in phase · OBV NEUTRAL
Current IV 83.2%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $775.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs SGMT Key Questions & Quantitative Answers

As of Nov 16, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (43.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus SGMT at $10.29 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. SGMT 43.1/100 HOLD), SGMT captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -77.6% operating margin) and revenue trajectory (+0.0% vs. +24.1% YoY). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SGMT trades in a Neutral technical trend (BREAKOUT options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with SGMT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while SGMT shifted N/A. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMT.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus SGMT (-24.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, SGMT carries 83.2% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.05β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.